ArticleNucleic acids research2026
Engineered suppressor tRNAs enable precise translational control of genetic circuits in E. coli.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Precise and orthogonal regulation of genetic circuits is a central challenge in synthetic biology, particularly at the translational level where tools remain scarce. Here, we address this by engineering suppressor transfer RNAs (sup-tRNAs) charged with canonical amino acids to enable programmable nonsense mutation readthrough in Escherichia coli. Screening of 20 variants revealed a clear sup-tRNA design rule: readthrough efficiency is dictated by the similarity of the native tRNA anticodon to amber codon (CUA), as it preserves native aaRS interactions. We then demonstrate the power of this tool for advanced genetic circuit engineering. First, in a LacI-based biosensor, sup-tRNA regulation reduced background leakage by >77% and increased the induction dynamic range by 4.3-fold (from 6.67 to 28.68). Second, by dynamically balancing glycolytic flux through targeted pykA and pykF regulation, we increased the titer of N-acetylneuraminic acid by 66% (from 5.33 to 8.82 g/l) without compromising cell growth. Our work establishes engineered cAA-charged sup-tRNAs as a versatile, efficient, and cost-effective platform for precision translational control within genetic circuits, opening new avenues for biosensor optimization and metabolic engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.